- Home
- SRTS vs FGEN Comparison
SRTS vs FGEN Comparison
Compare SRTS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRTS
- FGEN
- Stock Information
- Founded
- SRTS 2010
- FGEN 1993
- Country
- SRTS United States
- FGEN United States
- Employees
- SRTS N/A
- FGEN N/A
- Industry
- SRTS Medical/Dental Instruments
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SRTS Health Care
- FGEN Health Care
- Exchange
- SRTS Nasdaq
- FGEN Nasdaq
- Market Cap
- SRTS 51.8M
- FGEN 45.0M
- IPO Year
- SRTS 2016
- FGEN 2014
- Fundamental
- Price
- SRTS $3.45
- FGEN N/A
- Analyst Decision
- SRTS Strong Buy
- FGEN Strong Buy
- Analyst Count
- SRTS 3
- FGEN 2
- Target Price
- SRTS $8.00
- FGEN $146.50
- AVG Volume (30 Days)
- SRTS 88.0K
- FGEN 30.0K
- Earning Date
- SRTS 11-13-2025
- FGEN 11-11-2025
- Dividend Yield
- SRTS N/A
- FGEN N/A
- EPS Growth
- SRTS N/A
- FGEN N/A
- EPS
- SRTS N/A
- FGEN N/A
- Revenue
- SRTS $37,564,000.00
- FGEN $7,346,000.00
- Revenue This Year
- SRTS N/A
- FGEN N/A
- Revenue Next Year
- SRTS $46.14
- FGEN N/A
- P/E Ratio
- SRTS N/A
- FGEN N/A
- Revenue Growth
- SRTS 3.29
- FGEN N/A
- 52 Week Low
- SRTS $3.03
- FGEN $4.50
- 52 Week High
- SRTS $9.33
- FGEN $21.94
- Technical
- Relative Strength Index (RSI)
- SRTS 56.63
- FGEN 44.87
- Support Level
- SRTS $3.11
- FGEN $11.02
- Resistance Level
- SRTS $3.68
- FGEN $12.13
- Average True Range (ATR)
- SRTS 0.12
- FGEN 0.51
- MACD
- SRTS 0.09
- FGEN -0.22
- Stochastic Oscillator
- SRTS 75.32
- FGEN 2.56
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.